Speaker Profile
Venture Partner, 4BIO Capital
Biography
Tay Salimullah is a Venture Partner at 4BIO Capital and Managing General Partner of Renovamen Advisory LLC, offering strategic support to early-stage biotech, venture capital, and private equity firms. With over 20 years of leadership in rare diseases and MedTech, Tay has a proven record of scaling high-value technologies, including cell and gene therapies. At Novartis Gene Therapies, he transformed AveXis into a multibillion-dollar global business, pioneering Zolgensma's commercial model, securing approvals in 55+ countries, treating 4,000+ patients, and generating $5B+ in revenue. Earlier roles include a decade at Pfizer and strategic positions in investment and healthcare. Tays expertise spans drug development, market access, pricing, and operational excellence. He serves on the board of Trojenix and is a Fellow at the Alliance for Regenerative Medicine, advancing Cell and Gene Therapy Ethics and Society. Tay is passionate about driving innovation in regenerative medicine.
Session Abstract – PMWC 2025 Silicon Valley
Track Co-Chairs:
Yael Weiss, Mahzi Tx
Morten Sogaard, Astellas Gene Therapies
- PMWC 2025 Award Ceremony
Pioneer Honoree: James M. Wilson, Gemma Biotherapeutics
Luminary Honoree: Carolyn Bertozzi, Stanford
- Keynote: Bioorthogonal Chemistry, from Basic Science to Clinical Translation
- Carolyn Bertozzi, Stanford
- Keynote: The Promise of Genetic Medicines Unless You're Too Poor or Too Rare
- James M. Wilson, Gemma Biotherapeutics
- Barriers in Gene Therapy
Chair: Timothy Hunt, Alliance for Regenerative Medicine
- Tay Salimullah, 4BIO Capital
- James M. Wilson, Gemma Biotherapeutics
- Courtney Silverthorn, Bespoke Gene Therapy Consortium (BGTC) - Next-Generation Delivery Systems for Gene Therapies (PANEL)
Chair: James M. Wilson, Gemma Biotherapeutics
- Mathieu Nonnenmacher, Voyager Therapeutics
- Kevin Friedman, Kelonia Therapeutics
- Kunwoo Lee, GenEdit
- Haig Aghajanian, Capstan Therapeutics
- Beyond the Genome: Harnessing Epigenetics in Rare Disease Treatment (PANEL)
Chair: Charles Gersbach, Duke
- Prashant Mali, UCSD
- Nadav Ahituv, UCSF
- Blythe Sather, Tune Therapeutics
- Fyodor D Urnov, Berkely University
- Navigating the Regulatory Landscape for Gene and Cell Therapies (PANEL)
Chair: Yael Weiss, Mahzi Tx
- Rob Califf, FDA
- Courtney Silverthorn, Bespoke Gene Therapy Consortium (BGTC)
- Ben Dewees, Kyverna Therapeutics
- Paul Kruszka, GeneDx
- AI-driven Improvements in Gene and Cell Therapy (PANEL)
Chair: John Androsavich, Ginkgo Bioworks
- Francois Vigneault, Shape Therapeutics
- Eeshit Dhaval Vaishnav, Sequome
- Sam Sinai, Dyno Therapeutics
- Kira Radinsky, mana.bio
